ABT-450/r

DRUG2 trials

Sponsors

AbbVie (prior sponsor, Abbott)

Conditions

Chronic Hepatitis CHepatitis C, Chronic

Phase 2

A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study

CompletedNCT01609933

AbbVie (prior sponsor, Abbott)Chronic Hepatitis C

Start: 2012-12-18End: 2017-05-03Updated: 2018-06-19

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection

CompletedNCT01685203

AbbVie (prior sponsor, Abbott)Hepatitis C, Chronic

Start: 2012-08-31End: 2015-02-28Updated: 2021-07-30

Related Papers

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection.

2019-02-13

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.

2015-07-1166 citations

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.

2015-03-31189 citations